Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Verpasep caltespen

Drug Profile

Verpasep caltespen

Alternative Names: BCG65-E7; HspE7; Oncocine HspE7; R1461; SGN-00101

Latest Information Update: 18 Mar 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nventa Biopharmaceuticals Corporation
  • Developer Akela Pharma
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Recurrent respiratory papillomatosis

Highest Development Phases

  • Discontinued Anal dysplasia; Cervical cancer; Cervical dysplasia; Cervical intraepithelial neoplasia; Human papillomavirus infections; Recurrent respiratory papillomatosis

Most Recent Events

  • 14 Mar 2013 Akela Pharma and its subsidiaries cease operations
  • 25 Feb 2013 Discontinued - Phase-I for Cervical intraepithelial neoplasia in USA (SC; new formulation)
  • 25 Feb 2013 Discontinued - Phase-II for Cervical cancer in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top